Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...
It's part of a class of drugs known as GLP-1 receptor agonists, which also includes Ozempic, Wegovy and Zepbound."It ...
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...
A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...